Navigation Links
BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
Date:4/5/2011

RALEIGH, N.C., April 5, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today completion of enrollment in its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain.

(Logo: https://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

"The completion of enrollment in our Phase 3 efficacy study marks another very important milestone in our clinical development program for BEMA Buprenorphine in the management of chronic pain," stated Dr. Andrew Finn, Executive Vice President of Product Development at BDSI.  "We are very pleased to have achieved our aggressive recruitment and enrollment goals.  This milestone keeps us on target for reporting top-line study results in the third quarter of this year and is consistent with a timeline that would allow for a New Drug Application (NDA) to be filed in the second quarter of 2012."

BDSI believes that there remains a significant unmet medical need for potent new analgesics for the treatment of chronic pain.  The company believes that buprenorphine is an attractive option for development because of its potent analgesic properties, its differentiating characteristics from other opioids and its DEA Schedule III designation, which means there is less addiction potential than Schedule II products.  In addition, BEMA Buprenorphine has the potential to be the first oral transmucosal form of buprenorphine to treat chronic pain in the U.S.  According to Wolters Kluwer, opioid analgesic sales in the U.S. are in excess of $10 billion and growing, and BDSI believes that BEMA Buprenorphine has the potential to exceed $500 million in peak annual sales.

Additional Information on Phase 3 Study Design (BUP-301)

This Phase 3 trial of BEMA Buprenorphine (referred to as BUP-301) is
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
2. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
3. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
4. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
5. TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS SciFinder®
6. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
7. Caliper Life Sciences Launches Novel COX-2 Probe to Enable Personalized Medicine Research
8. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
9. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
10. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
11. Newborn Possibilities Fund Awards Grant to Georgia Health Sciences University Foundation to Support Groundbreaking Pediatric Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary ... common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... , May 25 A record 235 new ... being developed by America,s pharmaceutical research and biotechnology companies, according to a ... , , ... adult population suffers from diabetes—a rate that has more than doubled since ...
... HELMOND, The Netherlands , May 25, 2010 Blue Medical ... life of,patients with cardiovascular disease, with the start of the PIONEER trial, in,which ... , , ... clinical program, is the trial that,enables for the first time the delivery of ...
Cached Medicine Technology:New Report Shows Record Number of Medicines Currently in Development to Treat Diabetes 2New Report Shows Record Number of Medicines Currently in Development to Treat Diabetes 3New Report Shows Record Number of Medicines Currently in Development to Treat Diabetes 4First Coronary Stent on Drug Eluting Balloon Implanted 2
(Date:4/15/2014)... RECIST Working Group published in the European Journal of ... categorization of tumor response or various aspects of progression could ... They found that modeling target lesion tumor growth did not ... of the other components of progression. The RECIST Working Group ...
(Date:4/14/2014)... been made in chemotherapy over the past decade, but ... continues to be a major challenge. , Nanotechnology ... the use of nanocarriers, or capsules, that can transport ... body. , The catch? These carriers are tiny, and ...
(Date:4/14/2014)... Henry Ford Hospital reached a medical milestone April 3, ... novel way to access the heart. , Henry Ford ... the unique procedure called transcaval valve replacement, which accesses ... Northern Michigan resident Viola Waller, 80, underwent Henry Ford,s ...
(Date:4/14/2014)... , , Penicillin, one of the scientific marvels of the ... it once won against bacterial infections. But scientists at ... new approach to restoring its combat effectiveness, even against ... the power of the penicillin family of drugs since ...
(Date:4/14/2014)... an active role in their radiation treatment decisions leaves ... may even relieve psychological distress around the experience, researchers ... University of Pennsylvania report in the journal ... undergoing radiation treatment, Neha Vapiwala, MD , an ...
Breaking Medicine News(10 mins):Health News:Can refined categorization improve prediction of patient survival in RECIST 1.1? 2Health News:Nano shake-up 2Health News:Henry Ford Hospital hits new heart valve surgery milestone 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:Shared decision making during radiation therapy improves patient satisfaction 2Health News:Shared decision making during radiation therapy improves patient satisfaction 3
... Each year the American Institute of Biological Sciences ... contributions to the biological sciences. The AIBS ... to announce the following award winners for 2009: ... PhD, University of Washington, Outstanding Service Award: Robert ...
... Calif., May 15 Cord Blood America, Inc. (OTC ... preservation company ( http://www.cordblood-america.com ) ... cells to families nationwide and internationally, said today that ... In audio interview with analyst Francis Gaskins, explains the ...
... 15 The YWCA USA presented its prestigious 2009 ... Justice and YWCA Niagara for Women,s Economic Advancement at ... Washington, D.C. They were selected among six exemplary initiatives ... , , YWCA Central Massachusetts was honored ...
... Cigna Medical Group has announced the opening of its ... the total number of CareToday clinics to six.CareToday Anthem ... Daisy Mountain Drive and Gavilan Peak Parkway, 39510 North ... practitioners and physician assistants, the clinics offer after hours ...
... to be the fourth fatality in the U.S. , , FRIDAY, ... the swine flu outbreak has yet to run its current ... schools were closed Thursday after dozens of flu-like infections surfaced ... ventilator, according to published reports. , Meanwhile, a woman in ...
... with trastuzumab (Herceptin) to treat women who have metastatic ... their treatment options. , At the 45th Annual Meeting ... (ASCO), researchers from the Mayo Clinic campus ... vinorelbine, and trastuzumab offers a treatment option that is ...
Cached Medicine News:Health News:AIBS honors outstanding contributions to biology 2Health News:AIBS honors outstanding contributions to biology 3Health News:AIBS honors outstanding contributions to biology 4Health News:AIBS honors outstanding contributions to biology 5Health News:Cord Blood America CEO Matthew Schissler Expands on Thought Process in Owning Stem Cell Laboratory 2Health News:Cord Blood America CEO Matthew Schissler Expands on Thought Process in Owning Stem Cell Laboratory 3Health News:YWCA USA 2009 Hallmark Initiative Awards Presented to YWCA Central Massachusetts and YWCA Niagara 2Health News:Cigna Medical Group Announces Grand Opening of CareToday Clinic in Anthem, Ariz. 2Health News:Swine Flu Closes Three Schools in NYC 2Health News:Swine Flu Closes Three Schools in NYC 3Health News:Swine Flu Closes Three Schools in NYC 4Health News:Swine Flu Closes Three Schools in NYC 5Health News:Swine Flu Closes Three Schools in NYC 6Health News:Swine Flu Closes Three Schools in NYC 7Health News:Swine Flu Closes Three Schools in NYC 8Health News:Swine Flu Closes Three Schools in NYC 9Health News:Triple drug combination is promising option to treat metastatic HER2+ breast cancer 2Health News:Triple drug combination is promising option to treat metastatic HER2+ breast cancer 3
Shafts angled 45 degrees, 10 mm from tip to bend. 1 x 2 teeth. Serrated handle with polished finish. Most popular size or model....
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Serrated tips, straight platforms....
Curved shafts with fine pointed tips. Smooth handle with dull finish....
Medicine Products: